The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fifty‐ two—Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone
Abstract
ABSTRACT: Men with the metabolic syndrome (MetS) and type 2 diabetes (T2D) often have low testosterone levels. Elevating low testosterone levels may improve features of the MetS and glycemic control. In a single blind, 52‐week randomized clinical trial, the effects of supervised diet and exercise (D&E) with or without transdermal testosterone administration on components of the MetS in hypogonadal men with the MetS and newly diagnosed T2D were assessed. A total of 32 hypogonadal men (total testosterone <12.0 nmol/L) with newly diagnosed T2D and with the MetS as defined by the Adult Treatment Panel III and the International Diabetes Federation received supervised D&E, but 16 received it in combination with testosterone gel (50 mg) once daily (n = 16). No glucose‐lowering agents were administered prior to or during the study period. Outcome measures were components of the MetS as defined by the Adult Treatment Panel III and the International Diabetes Federation. Serum testosterone, glycosylated hemoglobin (HbA 1c), fasting plasma glucose, high‐density lipoprotein cholesterol, triglyceride concentrations, and the waist circumference improved in both treatment groups after 52 weeks of treatment. Addition of testosterone significantly further improved these measures compared with D&E alone. All D&E plus testosterone patients reached the HbA 1c goal of less than 7.0%; 87.5% of them reached an HbA 1c of less than 6.5%. Based on Adult Treatment Panel III guidelines, 81.3% of the patients randomized to D&E plus testosterone no longer matched the criteria of the MetS, whereas 31.3% of the D&E alone participants did. Additionally, testosterone treatment improved insulin sensitivity, adiponectin, and high‐sensitivity C‐reactive protein. Addition of testosterone to supervised D&E results in greater therapeutic improvements of glycemic control and reverses the MetS after 52 weeks of treatment in hypogonadal patients with the MetS and newly diagnosed T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While a small, uncontrolled study found that testosterone treatment augmented the reductions in central adiposity and insulin resistance achieved with lifestyle;118”
From Lowered testosterone in male obesity: Mechanisms, morbidity and management (2014) · cites this paper as [118]
In the citing paper
“The addition of testosterone gel to the lifestyle changes resulted in greater improvements of glycemic control and insulin sensitivity [22].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [22]
In the citing paper
“Heufelder et al. found that a lifestyle intervention (supervised diet and exercise) during 52 weeks significantly improved testosterone concentrations and glycemic control in 16 hypogonadal men with metabolic syndrome and newly diagnosed type 2 diabetes.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [22]
In the citing paper
“Heufelder et al. found that a lifestyle intervention (supervised diet and exercise) during 52 weeks significantly improved testosterone concentrations and glycemic control in 16 hypogonadal men with metabolic syndrome and newly diagnosed type 2 diabetes.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [22]
In the citing paper
“Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“An increase was found to occur after 3 months increasing further during 12 months (43), after 6 months, (35) or close to 1 year (44). Continuous increase was observed over 24 months (32).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“A decline in HbA1c was observed after 3 months (31, 36, 43) with further decrease after 12 months (43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“Several studies indicate that upon testosterone administration, serum glucose is reduced after 3 months in men with impaired glucose tolerance (31, 36, 43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“A decrease in serum proinsulin and insulin was noted after 3 months (43) or 6 months (45), and a decrease in homeostasis model assessment index of insulin resistance (HOMA-IR) after 3 months (36) or 6 months (45–47).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“A decrease in C-reactive protein (CRP) was observed after 3 weeks (63) and in other studies after 3 months (32, 43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“Other studies have found a rise of PSA levels after 3 months (40), some only after 12 months (43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [43]
In the citing paper
“Only few studies to date reported that combination of TRT and LSM is superior to LSM alone in increasing insulin sensitivity, glycemic control, muscle mass and reducing liver fat (4, 5).”
From Effects of liraglutide on obesity-associated functional hypogonadism in men (2019) · cites this paper as [4]
In the citing paper
“A compelling number of clinical studies demonstrated that TRT led to improvement in glycemic control and insulin sensitivity (4, 5, 37, 42), whereas some failed to confirm these observations (43).”
From Effects of liraglutide on obesity-associated functional hypogonadism in men (2019) · cites this paper as [4]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Lévy, J., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,023
Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
The Metabolic Syndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease
Haffner, S. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.010 · Cited by 568
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men
Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K.-F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1636 · Cited by 472
Endogenous sex hormones and metabolic syndrome in aging men
Muller, M., Grobbee, D. E., den Tonkelaar, I., Lamberts, S. W. J., & van der Schouw, Y. T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1158 · Cited by 456
Cited by
Sorted by citations
Items 101–200 of 348
Adverse health effects of testosterone deficiency (TD) in men
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.010 · Cited by 51
Ramasamy, R., Scovell, J. M., Kovac, J. R., & Lipshultz, L. I. (2014) · Journal of Urology · doi:10.1016/j.juro.2014.03.089 · Cited by 84
Clark, J. (2016) · Biology of Sport · doi:10.5604/20831862.1212974 · Cited by 50
Kim, S. H., Park, J. J., Kim, K. H., Yang, H. J., Kim, D. S., Lee, C. H., Jeon, Y. S., Shim, S. R., & Kim, J. H. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02876-w · Cited by 47
The 20-Year Public Health Impact and Direct Cost of Testosterone Deficiency in U.S. Men
Moskovic, D. J., de Araújo, A. B., Lipshultz, L. I., & Khera, M. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02944.x · Cited by 47
Konaka, H., Sugimoto, K., Orikasa, H., Iwamoto, T., Takamura, T., Takeda, Y., Shigehara, K., Iijima, M., Koh, E., Namiki, M., et al. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.148720 · Cited by 45
An update on male hypogonadism therapy
Surampudi, P. N., Swerdloff, R. S., & Wang, C. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.913022 · Cited by 46
Permpongkosol, S., Tantirangsee, N., & Ratana-olarn, K. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01994.x · Cited by 44
Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.10.001 · Cited by 46
The Role of testosterone treatment in patients with metabolic disorders
Corona, G., Rastrelli, G., Vignozzi, L., Barbonetti, A., Sforza, A., Mannucci, E., & Maggi, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1938548 · Cited by 46
Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity
Fernandez-Garcia, J.-C., Molina‐Vega, M., Muñoz-Garach, A., Damas-Fuentes, M., & Tinahones, F. J. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_44_18 · Cited by 49
Patient satisfaction with testosterone replacement therapies: the reasons behind the choices
Kovac, J. R., Rajanahally, S., Smith, R. P., Coward, R. M., Lamb, D. J., & Lipshultz, L. I. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12369 · Cited by 42
Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review
O’Rourke, T. K., & Wosnitzer, M. S. (2016) · Current Urology Reports · doi:10.1007/s11934-016-0634-y · Cited by 43
Ho, C.-H., Yu, H.-J., Wang, C.-Y., Jaw, F.-S., Hsieh, J.-T., Liao, W.-C., Pu, Y.-S., & Liu, S.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074173 · Cited by 40
Morales, Á., Bella, A. J., Chun, S., Jc, L., Assimakopoulos, P., Bebb, R. A., Gottesman, I. S., Alarie, P., Dugré, H., & Elliott, S. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.880 · Cited by 40
Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications
Kumar, M., Dutta, D., Anne, B., Shivaprasad, Sinha, A., Ray, S., & Chowdhury, S. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s50777 · Cited by 42
Predictive value of serum testosterone for type 2 diabetes risk assessment in men
Atlantis, E. E., Fahey, P. P., Martin, S., O’Loughlin, P. D., Taylor, A. W., Adams, R., Shi, Z., & Wittert, G. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0109-7 · Cited by 42
Troncoso, M. F., Pávez, M., Wilson, C., Lagos, D., Duran, J., Ramos, S., Barrientos, G. C., Silva, P., Llanos, P., Basualto-Alarcón, C., et al. (2021) · Biological Research · doi:10.1186/s40659-021-00328-4 · Cited by 41
Saad, F. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2354 · Cited by 37
Self-citationWittert, G., Atlantis, E. E., Allan, C. A., Bracken, K., Conway, A. J., Daniel, M., Gebski, V., Grossmann, M., Hague, W. E., Handelsman, D. J., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13601 · Cited by 36
Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone
Caliber, M., & Saad, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.002 · Cited by 38
Self-citationJuang, P. S., Peng, S., Allehmazedeh, K., Shah, A., Coviello, A. D., & Herbst, K. L. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12368 · Cited by 36
Høst, C., Bojesen, A., Erlandsen, M., Groth, K. A., Kristensen, K., Jurik, A. G., Birkebæk, N., & Gravholt, C. H. (2019) · Endocrine Connections · doi:10.1530/ec-19-0323 · Cited by 35
Traish, A. M., Abdallah, B., & Yu, G. W. (2011) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2011.132 · Cited by 37
Sex steroids and glucose metabolism
Allan, C. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122589 · Cited by 38
Brooke, J. C., Walter, D., Kapoor, D., Marsh, H., Muraleedharan, V., & Jones, T. H. (2014) · Andrology · doi:10.1111/j.2047-2927.2013.00177.x · Cited by 37
Testosterone and metabolic syndrome: The link
Ranabir, S., Kshetrimayum, A., & Reetu, K. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94248 · Cited by 38
Kumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., et al. (2023) · Clinics and Practice · doi:10.3390/clinpract13020041 · Cited by 36
Taylor, S. R., Meadowcraft, L., & Williamson, B. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1623 · Cited by 34
Multiple Mechanisms Linking Type 2 Diabetes and Alzheimer’s Disease: Testosterone as a Modifier
Asih, P. R., Tegg, M., Sohrabi, H. R., Carruthers, M. E., Gandy, S., Saad, F., Verdile, G., Ittner, L. M., & Martins, R. N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161259 · Cited by 34
Self-citationTestosterone Replacement Therapy and Mortality in Older Men
Hackett, G. I. (2015) · Drug Safety · doi:10.1007/s40264-015-0348-y · Cited by 34
Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status
Fui, M. N. T., Hoermann, R., Cheung, A. S., Gianatti, E., Zajac, J. D., & Grossmann, M. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00124.x · Cited by 33
Yassin, A. A., Salman, M., Alzubaidi, R. T., & Yassin, D. (2017) · The Aging Male · doi:10.1080/13685538.2017.1298584 · Cited by 33
Déficit de testosterona, síndrome metabólico y diabetes mellitus
Fernández-Miró, M., Chillarón, J. J., & Pedro‐Botet, J. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.06.020 · Cited by 33
Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome
Louters, M., Pearlman, M., Solsrud, E., & Pearlman, A. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00496-7 · Cited by 32
Male hormones and men's quality of life
Khera, M. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000256 · Cited by 33
Antonič, K. G., Antonič, B., Žuran, I., & Pfeifer, M. (2020) · The Aging Male · doi:10.1080/13685538.2020.1793132 · Cited by 33
Influence of Androgens on Circulating Adiponectin in Male and Female Rodents
Yarrow, J. F., Beggs, L. A., Conover, C. F., McCoy, S. C., Beck, D. T., & Borst, S. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047315 · Cited by 33
Metabolic syndrome and hypogonadism – two peas in a pod
Ebrahimi, F., & Christ‐Crain, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14283 · Cited by 32
International web survey shows high prevalence of symptomatic testosterone deficiency in men
TRINICK, T. R., Feneley, M. R., Welford, H., & Carruthers, M. E. (2010) · The Aging Male · doi:10.3109/13685538.2010.511325 · Cited by 31
Guay, A. T., & Traish, A. M. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.02.004 · Cited by 32
Yassin, A. A., Alwani, M. M., Alzubaidi, R. T., Almehmadi, Y., Nettleship, J. E., Al‐Rumaihi, K., Albaba, B., Kelly, D. M., & Saad, F. (2020) · The Aging Male · doi:10.1080/13685538.2020.1867094 · Cited by 31
Self-citationBagheri, P., Khalili, D., Seif, M., & Rezaianzadeh, A. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00716-7 · Cited by 30
Gooren, L. J., & Behre, H. M. (2012) · The Aging Male · doi:10.3109/13685538.2011.650246 · Cited by 30
Self-citationTraish, A. M., & Johansen, V. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.180032 · Cited by 32
Kumar, S., Khatri, M., Memon, R. A., Llerena-Velastegui, J., Zumbana-Podaneva, K., Benitez-Gutierrez, D., Nadeem, B., Anumolu, A. R., Azhar, M., & Zain, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102588 · Cited by 30
Androgen Deficiency in Aging and Metabolically Challenged Men
Shelton, J. B., & Rajfer, J. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.09.007 · Cited by 30
Androgens and male aging: current evidence of safety and efficacy
Gooren, L. J. (2010) · Asian Journal of Andrology · doi:10.1038/aja.2010.4 · Cited by 29
Self-citationSteeves, J. A., Fitzhugh, E. C., Bradwin, G., McGlynn, K. A., Platz, E. A., & Joshu, C. E. (2016) · Andrology · doi:10.1111/andr.12169 · Cited by 29
Magnussen, L. V., Andersen, P. E., Diaz, A., Ostojic, J. N., Højlund, K., HOUGAARD, D. M., Christensen, A. N., Nielsen, T. L., & Andersen, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0071 · Cited by 29
Cangüven, Ö., Talib, R. A., Ansari, W. E., Yassin, D., Salman, M., & Al-Ansari, A. A. (2017) · Andrologia · doi:10.1111/and.12768 · Cited by 27
Mohammed, M., Al‐Habori, M., Abdullateef, A. A., & Saif-Ali, R. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4926789 · Cited by 29
Androgens and the Regulation of Adiposity and Body Fat Distribution in Humans
Tchernof, A., Brochu, D., Maltais‐Payette, I., Mansour, M. F., Marchand, G. B., Carreau, A., & Kapeluto, J. (2018) · Comprehensive physiology · doi:10.1002/j.2040-4603.2018.tb00043.x · Cited by 27
Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.004 · Cited by 27
Testosterone deficiency and cardiovascular mortality
Morgentaler, A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.143248 · Cited by 28
Testosterone deficiency: myth, facts, and controversy.
Miner, M. M., Barkin, J., & Rosenberg, M. T. (2014) · PubMed · Cited by 27
Effects of Bariatric Surgery in Male Obesity-Associated Hypogonadism
Rigon, F. A., Ronsoni, M. F., Hohl, A., & van de Sande-Lee, S. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03829-0 · Cited by 27
Androgen deficiency and type 2 diabetes mellitus
Gibb, F. W., & Strachan, M. W. J. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.04.004 · Cited by 29
Connecting the Lines between Hypogonadism and Atherosclerosis
Fahed, A. C., Gholmieh, J. M., & Azar, S. T. (2012) · International Journal of Endocrinology · doi:10.1155/2012/793953 · Cited by 28
Mansoori, A., Hosseini, S., Zilaee, M., Hormoznejad, R., & Fathi, M. (2020) · Phytotherapy Research · doi:10.1002/ptr.6627 · Cited by 29
Accuracy of Testosterone Concentrations in Compounded Testosterone Products
Grober, E. D., Garbens, A., Božović, A., Kulasingam, V., Fanipour, M., & Diamandis, E. P. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12898 · Cited by 27
Hypogonadism and metabolic syndrome: review and update
Berg, W. T., & Miner, M. M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000582 · Cited by 26
Testosterone Replacement Therapy in Men with Prostate Cancer: A Time-Varying Analysis
Kaplan, A. L., Lenis, A. T., Shah, A., Rajfer, J., & Hu, J. C. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12768 · Cited by 26
Al-Qudimat, A. R., Al‐Zoubi, R. M., Yassin, A. A., Alwani, M. M., Aboumarzouk, O. M., Al‐Rumaihi, K., Talib, R. A., & Ansari, A. A. (2021) · Arab Journal of Urology · doi:10.1080/2090598x.2021.1959261 · Cited by 25
Androgen deficiency and metabolic syndrome in men.
Winter, A. G., Zhao, F., & Lee, R. K. (2014) · PubMed Central · doi:10.3978/j.issn.2223-4683.2014.01.04 · Cited by 27
Alwani, M. M., Yassin, A. A., Talib, R. A., Al-Qudimat, A. R., Aboumarzouk, O. M., Al‐Zoubi, R. M., Saad, F., Haider, K. S., & Ansari, A. A. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s309714 · Cited by 25
Self-citationScreening for hypogonadism in diabetes 2008/9: Results from the Cheshire Primary Care cohort
Anderson, S. G., Heald, A. H., Younger, N. O. M., Bujawansa, S., Narayanan, R. P., McCulloch, A. J., & Jones, H. T. (2011) · Primary care diabetes · doi:10.1016/j.pcd.2011.07.006 · Cited by 24
12-Month Observation of Testosterone Replacement Effectiveness in a General Population of Men
Miner, M. M., Bhattacharya, R. K., Blick, G., Kushner, H., & Khera, M. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.03.2637 · Cited by 25
Park, M. G., Cho, D.-Y., Yeo, J. K., Cho, S. I., Jung, J., Yang, S., Kong, D.-H., Ha, J. K., & Kim, J.-D. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.184269 · Cited by 23
Zhang, J., Yang, B., Xiao, W., Li, X., & Li, H. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2256-0 · Cited by 23
Effects of Testosterone Treatment on Quality of Life in Patients With Chronic Kidney Disease
Yeo, J. K., Koo, H., Yu, J., & Park, M. G. (2020) · American Journal of Men s Health · doi:10.1177/1557988320917258 · Cited by 22
Androgens regulate MMPs and the cellular processes of intimal hyperplasia
Mountain, D. J. H., Freeman, B. M., Kirkpatrick, S. S., Beddies, J. W., Arnold, J. D., Freeman, M. B., Goldman, M. H., Stevens, S. L., Klein, F. A., & Grandas, O. H. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.05.070 · Cited by 22
New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men
Karakas, S. E., & Surampudi, P. N. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.06.001 · Cited by 23
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Kırlangıç, O. F., Yilmaz‐Oral, D., Kaya‐Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., Khanam, A., Öztekin, Ç. V., & Gür, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.02.006 · Cited by 23
Madhu, S. V., Aslam, M., Aiman, A., Siddiqui, A. A., & Dwivedi, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.195999 · Cited by 22
Men’s Health in Primary Care: An Emerging Paradigm of Sexual Function and Cardiometabolic Risk
Miner, M. M. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.09.003 · Cited by 21
Tao, S., & Li, Z. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1092480 · Cited by 21
Hassan, J., & Barkin, J. (2016) · PubMed · Cited by 21
Testosterone Replacement Therapy and Components of the Metabolic Syndrome
Anaissie, J. E., Roberts, N. H., Wang, P., & Yafi, F. A. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.01.003 · Cited by 21
Testosterone as a marker of coronary artery disease severity in middle aged males
Gururani, K., Jose, J., & George, P. V. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.07.002 · Cited by 20
Zhang, K., Zhao, M. ‐., An, Q., Jia, Y., Fu, L., Xu, J., & Gu, Y. (2017) · Andrology · doi:10.1111/andr.12425 · Cited by 21
The prevalence of prediabetes in population of polish men with late-onset hypogonadism
Rabijewski, M., Papierska, L., & Piątkiewicz, P. (2014) · The Aging Male · doi:10.3109/13685538.2014.936000 · Cited by 19
Cardiovascular effects of hormone therapy for prostate cancer
Mason, M. D., & Lester, J. F. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s50549 · Cited by 24
Chinnappan, S. M., George, A. A., Pandey, P., Narke, G., & Choudhary, Y. K. (2021) · Food & Nutrition Research · doi:10.29219/fnr.v65.5647 · Cited by 21
Rasul, S., İlhan, A., Schernthaner-Reiter, M. H., Baumgartner-Parzer, S. M., & Kautzky‐Willer, A. (2011) · Gender Medicine · doi:10.1016/j.genm.2011.01.004 · Cited by 20
Advances in the treatment of functional male hypogonadism
Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., Sforza, A., & Maggi, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2296022 · Cited by 19
Testosterone deficiency, metabolic syndrome and diabetes mellitus
Fernández-Miró, M., Chillarón, J. J., & Pedro‐Botet, J. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.06.002 · Cited by 18
Testosterone Deficiency, Cardiac Health, and Older Men
Hackett, G. I., Kirby, M. G., & Sinclair, A. J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/143763 · Cited by 17
Dedov, I. I., Mel'nichenko, G. A., Shestakova, M. V., Rozhivanov, R. V., Терехова, А. Л., Zilov, A. V., Ladygina, D. O., & Курбатов, Д. Г. (2017) · Obesity and metabolism · doi:10.14341/omet2017483-92 · Cited by 17
Testosterone Supplementation Therapy in the Treatment of Patients with Metabolic Syndrome
Kovac, J. R., Pastuszak, A. W., Lamb, D. J., & Lipshultz, L. I. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2843 · Cited by 18
Sexual Function in Men with Metabolic Syndrome
Lee, R. K., Chughtai, B. I., Te, A. E., & Kaplan, S. A. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.09.008 · Cited by 18
Lifestyle, metabolic disorders and male hypogonadism – A one-way ticket?
Crisóstomo, L., Pereira, S., Monteiro, M. P., Raposo, J. F., Oliveira, P. F., & Alves, M. G. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110945 · Cited by 19
Chasland, L. C., GREEN, D. J., Schlaich, M. P., Maiorana, A., Cooke, B. R., Cox, K. L., Naylor, L. H., & Yeap, B. B. (2021) · Clinical Endocrinology · doi:10.1111/cen.14442 · Cited by 19
Effects of androgens on glucose metabolism
Umapathysivam, M. M., Grossmann, M., & Wittert, G. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101654 · Cited by 18
The role of the urologist in the prevention and early detection of cardiovascular disease
Yassin, A. A., Saad, F., Haider, A., & Gooren, L. J. (2011) · Arab Journal of Urology · doi:10.1016/j.aju.2011.03.014 · Cited by 16
Self-citationSepu, N., Adeleye, J. O., & Kuti, M. A. (2021) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.11.014 · Cited by 16
Erectile dysfunction, diabetes and cardiovascular risk
Hackett, G. I. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.076 · Cited by 16
Effects of Exercise on Testosterone and Implications of Drug Abuse: A Review
Perreault, B., Hammond, N., & Thanos, P. K. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000546 · Cited by 15
Testosterone therapy improves well being and psychological health
Akerman, J., Kovac, J. R., & Lipshultz, L. I. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000440 · Cited by 16
Yeo, J. K., Cho, S. I., Park, S., Jo, S., Ha, J. K., Lee, J. W., Cho, S. Y., & Park, M. G. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.17030 · Cited by 14
Metadata
- Authors
- Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L.
- Affiliations
- Bayer (Germany) (DE)
- Gulf Medical University (AE)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Gooren, Louis
- Venue
- Journal of Andrology
- Publisher
- Wiley
- Published
- 2009-11-12
- Volume
- 30
- Issue
- 6
- Pages
- 726-733
- ISSN
- 0196-3635 (ISSN-L)
- 1939-4640
- OpenAlex
- W2132592917
- Cited by
- 349
- References
- 26
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 25 · 2021: 19 · 2020: 18 · 2019: 12 · 2018: 19 · 2017: 23 · 2016: 23 · 2015: 29 · 2014: 36 · 2013: 32 · 2012: 23
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Andrology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- transdermal testosterone, hypogonadism, metabolic syndrome, type 2 diabetes, diet and exercise, glycemic control, HbA1c, insulin sensitivity, adiponectin, C-reactive protein, newly diagnosed diabetes, testosterone gel
- MeSH terms
- Administration, Cutaneous, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Insulin Resistance, Cholesterol, HDL, Male, Testosterone, Triglycerides, Exercise, Metabolic Syndrome, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
